GLP-1 Receptor Agonists Associated with Reduced Cancer Risk in Patients with Type 2 Diabetes
GLP-1 medications may lower cancer risk for people with diabetes
This meta-analysis investigated the impact of GLP-1 receptor agonists on overall and site-specific cancer risks in adults with Type 2 Diabet…
New analysis suggests that GLP-1 receptor agonists might reduce the risk of several types of cancer in adults with Type 2 Diabetes.
Evaluating the Efficacy of GLP-1 Receptor Agonists in Patients with Parkinson's Disease
GLP-1 medications show no motor benefit for Parkinson's patients
A meta-analysis reveals that GLP-1 receptor agonists provide no significant motor or non-motor benefits for patients with idiopathic Parkins…
New data suggests GLP-1 receptor agonists do not improve movement or non-motor symptoms in people with Parkinson's disease.
GLP-1 receptor agonists combined with metformin most effectively reduce weight and BMI in PCOS
GLP-1 Combined With Metformin Shows Weight Loss For PCOS
This network meta-analysis evaluated GLP-1 receptor agonists, metformin, and myoinositol for managing polycystic ovary syndrome. The study f…
A combination of GLP-1 receptor agonists and metformin may be more effective for weight loss in women with polycystic ovary syndrome than ot…
GLP-1 receptor agonists are associated with a 3.587 risk ratio for hair loss in obese patients
Weight loss medications linked to higher risk of hair loss
This meta-analysis of interventional studies involving 4114 GLP-1 RA users found a significantly higher risk of hair loss compared to placeb…
New data shows people taking certain weight loss drugs may face a significantly higher risk of losing their hair.
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
Diabetes May Influence Risk and Progress of Neurological Disorders
This narrative review synthesizes evidence regarding the role of diabetes mellitus (DM) as a disease modifier across various neurological co…
New research suggests that diabetes can change how certain neurological conditions progress, potentially opening doors for new treatment opt…
GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1 Receptor Agonists Show Mixed Links to Mental Health
This meta-analysis investigated the causal associations between GLP-1 receptor agonists and various mental health outcomes including anxiety…
New research explores how GLP-1 receptor agonists relate to conditions like anxiety and depression, finding no clear genetic link to most di…
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
GLP-1 drugs before weight loss surgery: modest benefit, no extra risk
This meta-analysis of 5461 patients found that preoperative GLP-1 receptor agonist use led to moderate weight reduction (SMD 0.4, 4.87 kg vs…
Taking GLP-1 drugs before bariatric surgery helps drop a few extra pounds but doesn't boost long-term weight loss or raise complication risk…
Review of GLP-1RAs in Type 2 Diabetes and Atherosclerosis Mechanisms
Diabetes Drugs That May Protect Your Arteries From Clogging
This narrative review synthesizes evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Type 2 Diabetes and atherosclerosis. …
A class of diabetes drugs originally designed to lower blood sugar may also protect your arteries from the dangerous buildup that leads to h…
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
All glucagon-like peptide-1 receptor agonists Articles
- GLP-1 Receptor Agonists Associated with Reduced Cancer Risk in Patients with Type 2 Diabetes
- Evaluating the Efficacy of GLP-1 Receptor Agonists in Patients with Parkinson's Disease
- GLP-1 receptor agonists combined with metformin most effectively reduce weight and BMI in PCOS
- GLP-1 receptor agonists are associated with a 3.587 risk ratio for hair loss in obese patients
- Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
- GLP-1R exposure shows no causal link to most mental disorders except eating disorders
- GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
- Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
- Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
- Review of GLP-1RAs in Type 2 Diabetes and Atherosclerosis Mechanisms
- CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
- GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
- Expert meeting report reviews pharmacological strategies for acquired hypothalamic obesity
- GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
- Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
- GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis